Real-world antibiotic needs for resistant Gram-negative infections

  09 June 2020

More than 2·8 million antibiotic-resistant infections occur in the USA every year and more than 35 000 people die as a result, with estimated costs exceeding US$2 billion. Resistance in Gram-negative bacteria is increasing, particularly in certain populations at high risk. Over half of the antimicrobial resistance threats highlighted by the Centers for Disease Control and Prevention (CDC) are Gram-negative bacteria, including three of five urgent threats. Since resistance in Gram-negative bacteria is often mediated by plasmids carrying multiple resistance genes, treatment is frequently restricted to second-line and third-line antibiotics with high toxicity or poor efficacy, which causes patient harm and increases health care costs.

Author(s): Margaret A Fitzpatrick
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin